Investigational drug · Phase 3
INCB123667
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
8
Any phase or sponsor naming "INCB123667"
First trial start
2025
Nov 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INCB123667", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Cancer
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INCB123667" as an intervention, largest first.
- Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1Pivotal-lookingNot yet recruiting
Incyte CorporationIncyte (INCY)
NCT07797283 · 590 participants (planned) · Start Dec 1, 2026 · Primary completion May 1, 2032
Drug: INCB123667; Bevacizumab and 1 more · For: Ovarian Cancer
- Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT05238922 · 291 participants · Start Jul 5, 2022 · Primary completion Jul 27, 2027
Drug: INCB0123667; Palbociclib and 5 more · For: Solid Tumors
Sites: Duarte, California; Irvine, California; Los Angeles, California · 41 sites in all
Incyte CorporationIncyte (INCY)
NCT07023627 · 160 participants (planned) · Start Nov 12, 2025 · Primary completion Apr 27, 2027
Drug: INCB123667 · For: Ovarian Cancer
Sites: Mobile, Alabama; Los Angeles, California; San Diego, California · 74 sites in all
Incyte CorporationIncyte (INCY)
NCT06909162 · 51 participants · Start May 5, 2025 · Primary completion May 17, 2026
Drug: INCB123667; itraconazole and 1 more · For: Healthy Participants
Sites: Lincoln, Nebraska
Incyte CorporationIncyte (INCY)
NCT07559396 · 16 participants (planned) · Start May 29, 2026 · Primary completion Jan 4, 2027
Drug: INCB123667 · For: Renal Impairment
Sites: Miami Lakes, Florida; Orlando, Florida
Incyte CorporationIncyte (INCY)
NCT07559474 · 16 participants (planned) · Start May 27, 2026 · Primary completion Apr 13, 2027
Drug: INCB123667 · For: Hepatic Insufficiency; Liver Diseases
Sites: Chandler, Arizona; Orlando, Florida; San Antonio, Texas · 4 sites in all
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT07214779 · 13 participants · Start Dec 9, 2025 · Primary completion Oct 12, 2027
Drug: INCB123667; Investigator's choice of chemotherapy · For: Ovarian Cancer
Sites: Anchorage, Alaska; Tucson, Arizona; Duarte, California · 198 sites in all
Incyte CorporationIncyte (INCY)
NCT07218744 · 9 participants · Start Nov 13, 2025 · Primary completion Dec 10, 2025
Drug: INCB123667 · For: Healthy Participants
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- Cyclin E1 as a driver of oncogenesis; high grade serous ovarian cancer as an exemplar.
Taylor SJ, Gourley C · Crit Rev Oncol Hematol 2026
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.